
    
      This is a multi-center, long-term, open-label, expanded access protocol of adjunctive GNX
      treatment in children, adolescents, and adults with CDD. Patients with inadequate seizure
      control on their current anti seizure medications at therapeutic doses will be eligible for
      enrollment.
    
  